Inhibition of CDK7 was demonstrated using the selective CDK7 inhibitor YKL-5-124 to predominantly disrupt cell cycle progression and induce DNA replication stress and genomic instability in small cell lung cancer, while triggering immune response signaling. Here, CDK7 is linked to small cell lung carcinoma.